Lung cancer is the malignant tumor with the highest incidence and death rate in the world, and the 5-year survival rate is very low, only 16.8%. The situation in China is similar, as lung cancer is the number one cancer killer in China, with about 705,000 new cases and 569,000 deaths per year. With the high prevalence of lung cancer, it has caused great mental pressure to many families with the disease, and at the same time brought heavy financial burden to patients due to the treatment cost, especially to those families with average economic conditions, which are often seen to be in debt due to the disease. At present, the treatment of lung cancer requires a combination of surgery, chemotherapy, radiotherapy, targeted therapy, etc. Most patients in early stage will undergo surgical resection, but >70% of patients are already in advanced stage when diagnosed and have lost the chance of surgery, so systemic therapy is the main means, but the treatment effect is not so satisfactory. The median survival time of the standard platinum-containing two-drug regimen was 7.4~10.3 months, and the 1-year survival rate was 26%~43%, so the efficacy reached a bottleneck and it was difficult to make breakthroughs. At the beginning of the 21st century, with the deepening of molecular biology research, it is possible to classify non-small cell lung cancer into molecular phenotypes according to the different expression of various molecular markers, and to develop new drugs for targeted individualized molecular targeted therapy by targeting the driver genes related to tumor occurrence and development. Targeted therapies are highly effective and relatively less toxic for patients with appropriate gene mutation types, and are becoming more and more common in the treatment of lung cancer, playing an increasingly important role in the whole course of lung cancer treatment, however, these drugs are mostly produced by world-class joint venture pharmaceutical companies and are relatively expensive. It is gratifying to note that after the efforts of multiple departments, several targeted drugs have been launched for mainland residents under the charitable drug grant policy. Most of the conditions are relatively simple, after taking the drugs continuously for a specified period of time, after medical evaluation, it is determined that the patient is benefited, and the economic situation meets the criteria of drug donation, generally can apply for free drug donation, this initiative has largely reduced the economic pressure of patients. For example, the typical representative drugs for EGFR mutation in non-small cell lung cancer patients are Erlotinib (trade name: Troche), which costs about RMB 80,000 for 4 months of continuous use, Gefitinib (trade name: ERSA), which costs 5 months of continuous use, and Exotinib (trade name: Kemena), which costs 6 months of continuous use, for a total of about RMB 80,000. The cost is also all around 80,000 yuan, and eligible patients can also receive a charitable gift of the drug. In addition, the targeted drug crizotinib (trade name: Securitin), which targets EML4-ALK fusion mutations, costs around 210,000 yuan for 4 months of continuous use in the first year, and is eligible for the next 8 months of assistance; for 2 months of continuous use in the second year, it is eligible for the next 10 months of assistance. These targeted drugs bring clinical benefits to patients while greatly reducing their financial burden. The above is the charitable drug donation (PAP) situation of commonly used target drugs in lung cancer treatment, hoping to provide some valuable reference information for lung cancer patients and their families, and hoping that more target drugs can be developed and participate in the charitable program, so that more patients and families can be benefited. We also hope that as clinical experts continue to practice and accumulate experience in lung cancer research, they will be able to explore richer and more effective treatments to prolong patients’ lives and improve their quality of life.